Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Trial ID or NCT#

NCT04901806

Status

not recruiting iconNOT RECRUITING

Purpose

This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.

Official Title

A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Seema Nagpal, MD
Seema Nagpal, MD
Neuro-oncologist
Clinical Professor, Adult Neurology Clinical Professor (By courtesy), Neurosurgery
Chirag Patel, MD, PhD

Contact us to find out if this trial is right for you.

Contact

Neuro OnC Team
+1 650-723-4467

View on ClinicalTrials.gov